Clinical Study
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials
| | Source | Stent platform used | Age, mean, y (SD) | Unstable anginaor NSTEMI (%) | STEMI (%) | Diabetes Mellitus (%) |
Percentage of patients on dual antiplatelets at 1 year (%) | | EES | PES | EES | PES | EES | PES | EES | PES | EES | PES |
| | Kedhi et al. [6], 2010 | XIENCE V | TAXUS Liberté | 62.9 (55.4–71.1) | 63.6 (55.7–72.9) | 34 | 36 | EES 27
PES 23 | 17.1 | 19 | n/a | n/a |
| | Garg et al. [5], 2009 | XIENCE V | TAXUS Express or TAXUS Liberté | 62.0 (10.0) | 62.0 (9.0) | 27 | 32 | n/i | 23 | 24 | n/a | n/a |
| | Stone et al. [7], 2009 | XIENCE V | TAXUS EXPRESS2 | 63.2 (10.5) | 62.8 (10.2) | 18.7 | 25.1 | n/i | 29.6 | 27.9 | 71.7 | 71.7 |
| | Stone et al. [8], 2010 | XIENCE V | TAXUS Express | 63.3 (10.5) | 63.3 (10.2) | 27.7 | 28.9 | n/i | 32 | 32.5 | 91.9 | 92.2 |
|
|
Abbreviations: EES: everolimus-eluting stent; PES: paclitaxel-eluting stent; n/i: not included; n/a: not available; SD: standard deviation.
|
